Head and Neck Paragangliomas—A Genetic Overview
Autor: | Anna C. Majewska, Małgorzata Wierzbicka, Katarzyna Ziemnicka, Marek Ruchała, Bartłomiej Budny |
---|---|
Rok vydání: | 2020 |
Předmět: |
genetic syndromes
SDHB SDHA 030209 endocrinology & metabolism Review Neuroendocrine tumors Bioinformatics Catalysis Paraganglioma Inorganic Chemistry Pheochromocytoma 03 medical and health sciences head and neck neoplasms 0302 clinical medicine Germline mutation Humans Medicine Genetic Predisposition to Disease HRAS Physical and Theoretical Chemistry Molecular Biology Spectroscopy business.industry Organic Chemistry General Medicine mutations medicine.disease pheochromocytoma Computer Science Applications head and neck tumors 030220 oncology & carcinogenesis Mutation SDHD business |
Zdroj: | International Journal of Molecular Sciences |
ISSN: | 1422-0067 |
DOI: | 10.3390/ijms21207669 |
Popis: | Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors. Head and neck paragangliomas (HNPGL) can be categorized into carotid body tumors, which are the most common, as well as jugular, tympanic, and vagal paraganglioma. A review of the current literature was conducted to consolidate knowledge concerning PGL mutations, familial occurrence, and the practical application of this information. Available scientific databases were searched using the keywords head and neck paraganglioma and genetics, and 274 articles in PubMed and 1183 in ScienceDirect were found. From these articles, those concerning genetic changes in HNPGLs were selected. The aim of this review is to describe the known genetic changes and their practical applications. We found that the etiology of the tumors in question is based on genetic changes in the form of either germinal or somatic mutations. 40% of PCC and PGL have a predisposing germline mutation (including VHL, SDHB, SDHD, RET, NF1, THEM127, MAX, SDHC, SDHA, SDHAF2, HIF2A, HRAS, KIF1B, PHD2, and FH). Approximately 25–30% of cases are due to somatic mutations, such as RET, VHL, NF1, MAX, and HIF2A. The tumors were divided into three main clusters by the Cancer Genome Atlas (TCGA); namely, the pseudohypoxia group, the Wnt signaling group, and the kinase signaling group. The review also discusses genetic syndromes, epigenetic changes, and new testing technologies such as next-generation sequencing (NGS). |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |